Intrexon Corporation (XON) : Analyst Rating Update

Intrexon Corporation (XON) : The consensus on Intrexon Corporation (XON) based on 7 analyst recommendation on the company stock is 1.86, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Intrexon Corporation (XON) : 8 Wall Street analysts covering Intrexon Corporation (XON) believe that the average level the stock could reach for the short term is $48.13. The maximum price target given is $65 and the minimum target for short term is around $29, hence the standard deviation is calculated at $12.68.

Intrexon Corporation (NYSE:XON): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $24.85 and $24.78 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $25.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $25.89, notching a gain of 2.86% for the day. The total traded volume was 1,557,349 . The stock had closed at $25.17 on the previous day.

Also, JMP Securities initiates coverage on Intrexon Corporation (NYSE:XON) The brokerage firm has issued a Market Outperform rating on the shares. The rating by the firm was issued on May 3, 2016. The company shares have dropped -44.08% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $69.45 and the one year low was seen on Jan 14, 2016. The 50-Day Moving Average price is $26.81 and the 200 Day Moving Average price is recorded at $30.16.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.